Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

In vitro studies of Bruton’s tyrosine kinase (BTK) and PI3K inhibitors demonstrate synergy in non-Hodgkin lymphoma (NHL). Investigators thereby initiated a phase 1/1b clinical trial to evaluate the combination of ibrutinib (BTK inhibitor) and buparlisib (pan-PI3K inhibitor) in relapsed/refractory (RR) NHL.

Eligible patients had RR diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma (MCL), or follicular lymphoma (FL) with Eastern Cooperative Oncology Group performance status ≤2, and adequate organ function. Oral ibrutinib and buparlisib were given daily on a 28-day cycle. Dose reductions were permitted after cycle 1. Tumor response was examined and based on Lugano Classification; however, complete response (CR) required both positron emission tomography resolution and at least partial response (PR) by computed tomography.

Phase 1 dose escalation was completed with 16 evaluable patients: 7 patients with DLBCL, 6 patients with MCL, and 3 patients with FL. Of the 7 patients with DLBCL, 1 had CR and 1 had stable disease. In the 3 patients with FL, all had stable disease. In the 6 patients with MCL, 4 had CR and 2 had PR. Ten patients discontinued treatment for progression (5 patients with DLBCL, 2 patients with MCL, and 3 patients with FL).

In regard to safety, 50% of patients had a ≥grade 3 related adverse event. Most common related adverse events were hyperglycemia, diarrhea, elevation of total bilirubin, and thrombocytopenia. Cytomegalovirus reactivation was also observed in 4 patients but none required therapy. Neurologic adverse events, including mood changes, depression, anxiety, anemia, and confusion, were observed in 7 patients.

The combination of ibrutinib and buparlisib, while generally well-tolerated, has the predicted toxicities of both BTK and PI3K inhibitors. Particularly, promising efficacy is observed in MCL. The recommended phase 2 dose is ibrutinib 560 mg and buparlisib 100 mg, although dose reductions for tolerability may be necessary for long-term oral therapies and may influence the recommended phase 2 dose.

Batlevi CL, et al. ASCO Abstract 7544.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 9, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME